You are here

PROVID PHARMACEUTICALS INC.

Company Information
Address
7 DEERPARK DR STE M11
MONMOUTH JUNCTION, NJ 08852-1921
United States


http://www.provid.com

Information

UEI: TNNMX4JCPCE8

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. TRAIL Upregulation by TIC10 Analogs

    Amount: $224,960.00

    Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  2. F11R antagonists for atherosclerosis

    Amount: $175,200.00

    DESCRIPTION (provided by applicant): The proposed research is directed toward the discovery of novel peptide inhibitors of platelet adhesion to the inflamed endothelium that would have value in the pr ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  3. 402- RFP: N43-CM-87007-68 TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUEST

    Amount: $149,558.00

    This project aims to further develop 10-aryl deazaflavin compounds that have been shown to be inhibitors of HDM2's ubiquitin ligase.

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  4. MEDICINAL CHEMISTRY LEAD OPTIMIZATION, (PHASE II) SBIR TOPIC 198

    Amount: $150,000.00

    N/A

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  5. Design and Assay of DQ2 Inhibitors for Celiac Disease

    Amount: $106,881.00

    DESCRIPTION (provided by applicant): Celiac disease, also known as celiac sprue, is a inflammatory disease affecting the small intestine that results from an immunological reaction to dietary glutens ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  6. Inhibitors of Protein Kinase A Localization in the Heart

    Amount: $132,414.00

    DESCRIPTION (provided by applicant): Cell permeable peptide inhibitors of protein kinase (PKA) sub-cellular localization will be designed to identify signal transduction pathways in cardiac myocytes t ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  7. MEDICINAL CHEMISTRY LEAD OPTIMIZATION, (PHASE II) SBIR TOPIC 198

    Amount: $375,000.00

    N/A

    SBIRPhase II2005Department of Health and Human Services National Institutes of Health
  8. MEDICINAL CHEM LEAD OPTIMIZATION, SBIR TOPIC 198

    Amount: $109,991.00

    N/A

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  9. QBP1 Mimetics as Therapeutics for Huntington's Disease

    Amount: $187,995.00

    DESCRIPTION (provided by applicant): Polyglutamine diseases are a group of inherited neurodegenerative diseases, including Huntington's disease, caused by abnormal expansions of the polyglutamine stre ...

    STTRPhase I2004Department of Health and Human Services National Institutes of Health
  10. MHC Class II inhibitors for Multiple Sclerosis

    Amount: $109,997.00

    DESCRIPTION (provided by applicant): MS is an autoimmune disease affecting over 350,000 patients in the US in which the immune system attacks the myelin sheaths that insulate CNS axons, with secondary ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government